KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.Lancet Respir MedPMID 39756424PMC121841002025-Mar0.98未发现恶性肿瘤人群证据。待处理
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211.Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39788823无 PMCID2025-Mar0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。无 KM 图
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.Eur J Heart FailPMID 39792342PMC119553142025-Mar0.98未发现恶性肿瘤人群证据。待处理
Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen-reduced red cells in complex cardiac surgery patients.TransfusionPMID 39801369无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
Impact of Frailty on Antihypertensive Treatment in Older Adults.HypertensionPMID 39807596无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.LeukemiaPMID 39815052无 PMCID2025-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial.Lancet Gastroenterol Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39824200无 PMCID2025-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.Eur UrolPMID 39827019无 PMCID2025-Mar0.85The record describes an interim safety analysis from a phase 3 randomized trial in oncology, but it does not report the required survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes for KM digitization.待处理
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.Nat MedPMID 39863775PMC119227502025-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.Lancet Diabetes EndocrinolPMID 39870096无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
Effect of lemborexant on sleep architecture in participants with insomnia disorder and mild obstructive sleep apnea.Sleep MedPMID 39879708无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis.Circ Heart FailPMID 39882614无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
The Role of Serum Free Fatty Acids in Endothelium-Dependent Microvascular Function.Endocrinol Diabetes MetabPMID 39888728PMC117849022025-Mar0.98未发现恶性肿瘤人群证据。待处理
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39893774无 PMCID2025-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials.Lancet Respir MedPMID 39900091无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
Pressure pain threshold and perceived impact of pain differentially predict short-term and long-term pain reduction following acupuncture in fibromyalgia.J Integr MedPMID 39915157无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial.Lancet HaematolPMID 39919775无 PMCID2025-Mar0.85This is a randomized phase III trial in hematological malignancies with a primary time-to-event endpoint (disease-free survival). However, the intervention compares different graft sources (haploidentical PBSCs + unrelated cord blood vs. haploidentical PBSCs + bone marrow), which are cellular therapies/transplant procedures, not a drug-containing intervention. The eligibility criteria require a drug-containing intervention, which is not met here.待处理
Anesthesia-induced electroencephalogram oscillations and perioperative outcomes in older adults undergoing cardiac surgery.J Clin AnesthPMID 39921932PMC119536262025-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39923717无 PMCID2025-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.Adv TherPMID 39932677PMC118683612025-Mar0.98未发现恶性肿瘤人群证据。待处理
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial.Lancet HaematolPMID 39947215无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39952264无 PMCID2025-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial.Lancet HIVPMID 39954697PMC123383332025-Mar0.98未发现恶性肿瘤人群证据。待处理
Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.Mult Scler Relat DisordPMID 39965438无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 1:非 KM 图;Figure 2:森林图/亚组分析图。PMID 39985889PMC119045802025-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.EBioMedicinePMID 40020259PMC119193302025-Mar0.98未发现恶性肿瘤人群证据。待处理
Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study.Clin Transl SciPMID 40025846PMC118733652025-Mar0.95The record describes a Phase III randomized trial with a drug intervention in oncology, but the primary efficacy endpoint is not a time-to-event outcome (e.g., Kaplan-Meier or HR). The main results focus on MRD-negative CR rate and exposure-response analyses for safety and efficacy, which do not meet the required time-to-event efficacy endpoint criterion.待处理
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions.J Neuromuscul DisPMID 40033991PMC131428712025-Mar0.98未发现恶性肿瘤人群证据。待处理
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.J Neuromuscul DisPMID 40034001PMC131428682025-Mar0.98未发现恶性肿瘤人群证据。待处理
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.ESMO OpenPMID 40056850PMC119307162025-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia.Ann Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图。PMID 40063243PMC120319242025-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial.CNS DrugsPMID 40111738PMC119500992025-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy of Once-Nightly Sodium Oxybate in Patients with Narcolepsy: Post Hoc Analyses of Sensitivity, Effect Size, and Numbers Needed to Treat from the Phase 3 REST-ON Trial.CNS DrugsPMID 40111739PMC119501042025-Mar0.98未发现恶性肿瘤人群证据。待处理
Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India.JCO Glob OncolPMID 40127383无 PMCID2025-Mar0.98未发现恶性肿瘤人群证据。待处理
Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis.Arq Bras CardiolPMID 40243852PMC121077672025-Mar0.98未发现恶性肿瘤人群证据。待处理
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.N Engl J MedPMID 39651791PMC118649012025-Feb-270.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
A phase 3 clinical trial on the immunogenicity and safety of booster vaccination after Zagreb or Essen regimens.Sci RepPMID 40016280PMC118686202025-Feb-270.98未发现恶性肿瘤人群证据。待处理
The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial.Sci RepPMID 40016311PMC118684242025-Feb-270.98未发现恶性肿瘤人群证据。待处理
Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial.Stroke Vasc NeurolPMID 38858097PMC118774292025-Feb-250.98未发现恶性肿瘤人群证据。待处理
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.JAMAPMID 39671272PMC118629702025-Feb-250.95The study is a randomized Phase III trial in human oncology with a drug intervention and reports original results. However, the primary efficacy endpoint is pathological complete response (pCR), a binary endpoint, not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. No Kaplan-Meier analysis or hazard ratio for a time-to-event endpoint is mentioned in the abstract. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint.待处理
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.Eur J CancerPMID 39798264无 PMCID2025-Feb-250.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial.J Am Coll CardiolPMID 39846936无 PMCID2025-Feb-250.98未发现恶性肿瘤人群证据。待处理
Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.Eur J CancerPMID 39864363无 PMCID2025-Feb-250.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39879779无 PMCID2025-Feb-250.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip.BMC Musculoskelet DisordPMID 40001000PMC118532252025-Feb-250.98未发现恶性肿瘤人群证据。待处理
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial.Clin Infect DisPMID 39523543PMC118482842025-Feb-240.98未发现恶性肿瘤人群证据。待处理
Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial.BMJPMID 39993822PMC118486762025-Feb-240.98未发现恶性肿瘤人群证据。已完成
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.LancetPMID 39919773无 PMCID2025-Feb-220.98未发现恶性肿瘤人群证据。待处理
Intermittent screening using ultra-sensitive malaria rapid diagnostic test and treatment with pyronaridine-artesunate compared to standard preventive treatment with sulfadoxine-pyrimethamine for malaria prevention in pregnant women in Kinshasa, DRC.Malar JPMID 39985024PMC118463852025-Feb-210.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study.Medicine (Baltimore)PMID 39993074PMC118568782025-Feb-210.98未发现恶性肿瘤人群证据。待处理